So after another week in the stock market characterized by a contentious presidential debate, a failed stimulus package, the President coming down with the illness, and the President taking an experimental drug to cure this illness by a company that we're going to be talking about in this video. If you look at the therapeutics which I'm taking right now, some of them and others are coming out soon that are looking like, uh, frankly, they're miracles and a weak characterized by some more mixed jobs reports, many are coming back here to ask just one simple question and do you know what that question is? Well, that question is of course, what Charlie are the top three stocks for this week? Well, in this video, we're going to be talking about the top three stocks for this week. But ladies and gentlemen, before we talk about that, we have to first talk about what happened last week. Okay, last week we started with Uvxy and Svxy.

So Uvxy goes up essentially when uncertainty goes up, and as we are nearing an election with much uncertainty, I made the connection that Uv Xy and Svxy were great plays, and towards the beginning of the week, Svxy went strong and then later on in the week, Uv Xy started these beautiful uptrends, then gapped up Friday morning as it reacted to Trump's diagnosis. But one thing that we often talk about is this idea that if something gaps up a lot at once, that means that it has a lot more opportunity to cool off because you've already taken so much of the upside. and so it is always important to be direction independent on these. Okay, Next we spoke about Shll, which was due for an acquisition vote Monday morning.

It gapped up Monday morning, but there was actually some doubt cast on one of the provisions of the vote early on which caused this sell-off. But this was actually quite exciting because unlike this gap up play, the sell-off made it possible to get in on the action as we ran up to 54-45 and later on in the week after acquisition sunk in, the ticker symbol switched to H-y-l-n and the stock just sold off. This is why it is so important folks to trade the hype instead of just randomly hold it, holding and hoping is again, never never never a good idea. If you are holding aimlessly and you don't have a clear plan, well you're going to lose.

Next we spoke about Rite Aid. Now, Ryden had sold off on good earnings a couple weeks prior and we made the case that we are now gearing towards covet lows in that video. I said that I wanted to find a clear bottom this week, but under my breath I think many of you could tell that I did want it to correct. But what actually happened was that on Friday we did get what was the first suggestion of a bottom.

Yes, we did get a bottom, but it's too hard to say if this is a substantiated bottom so I would take you back to the analogy that we don't rush to just buy something because it's been beat down, but we wait for it to show signs of recovering. Okay, but before we get into this week's plays, I want to have a conversation with you. I want to remind you that every play that we talk about is a battlefield. And it's not just a regular battlefield, it's a dirty battlefield.

I can sit here and draw you out a map of where each battle is going to be. I could even tell you how I would fight the battle, but I can't fight the battle for you. You are the one that's actually going into battle, so it's up to you to know how to battle in the first place. We have tons of resources on this channel teaching you how to battle and you can't just haphazardly join battles.

Imagine if a lieutenant was like, go to battle soldier and then you say yes sir and you just randomly dive into a battle with your eyes closed and no weapons. Well, obviously that's going to end poorly and that's not something you should do, but so many of you do that when it comes to the stock market. So being a soldier in the stock market means having a clear plan, executing on said plan, and holding yourself accountable. as much as I'd love to hold you accountable and yell at you every single time you make a mistake.

The truth is that you have to hold yourself accountable. I can't be there to scream at you, although you could just replay my clips of me screaming every single time you make a mistake. But I rest my case. But anyways, folks, speaking of accountability, the one thing that you need to be accountable for is hitting that ravishing like button.

Account for all that travishiness. Okay and quick plug for folks who are looking to learn how to trade and are looking for structure for their trading education, are looking for our morning briefings and also want to work with us in our private chat. We do offer ziptraderu which is 50 off if you type in coupon code Stay Home 2020 before checkout. We'll go ahead and put the link in the description below so that you can decide whether or not we are a fit for your trading.

journey. To start, the President has been given an experimental drug to treat his covid along with a steroid usually reserved for severe patients with covet and a previously endorsed treatment from Gilead. So potential winners here. I'm thinking G-i-l-d and R-e-g-n and I sat here a long time trying to make up my mind on which to pick.

On one hand, Regn has more to gain by earning legitimacy, and on the other, Gilead has more upward potential as it's trading so low compared to its previous high, but neither of them have both of these elevating factors going for them at the same time. So here we have a situation where one stock is great in terms of the charts and one stock is great in terms of the catalyst, but neither have both of those going for it. Which means that I'm going to present all the facts and leave it to you to make up your mind on this. But we'll go ahead and start with the experimental drug.

So in the disclosure from the White House, they said they injected the President with Regeneron's antibody cocktail. This is a therapy that injects you with an artificial version of the antibodies the immune system naturally makes to fight off infection from Covid, but it's still in the preliminary stages now. One thing to know about this treatment is that the company put out a press release late September explaining that early phase data suggests that this cocktail reduces viral load and the time it takes to alleviate symptoms in non-hospitalized patients. But again, it's an experimental drug.

So essentially the President was given an unapproved drug to treat covet, and there's a few ways to speculate on what this actually means. On the surface, it does not make a lot of sense that the President would be injected with an unproven therapy for a virus that most people recover from without complications. Obviously, he is in a high-risk demographic, but at the same time, why would you inject him with an unproven therapy unless you thought that the current situation is very, very severe. So the speculation right now is that White House doctors felt that Trump's case was a lot more serious than they had let on.

But at the same time they are saying that Trump may be released early next week and he has gone on video saying that he's doing well and as I was making this video, he snuck out to go visit his supporters. So how bad can he really be feeling? But again, if you look at the way that covet affects most patients, you see that it's not that uncommon to see mild symptoms in the beginning, then a drastic escalation later on. So right now everything else is in limbo and this beginning of the week is going to be very, very instrumental. And in terms of stocks being affected by this, my two picks are R-e-g-n and G-i-l-d But R-e-g-n has a lot more to gain by the publicity because it's the more speculative of the treatments.

So the legitimacy gained by the President taking it is going to have more of a benefit for regn than it would for Gild, because gild was pretty much already widely endorsed product. So when a President takes an experimental treatment from a company, it obviously brings a lot of publicity and legitimacy to it. Even if the Fda doesn't specifically say it works, folks, think well. if it's good enough for the President of the United States, then it must be good enough for the rest of the population.

in which case, that could certainly make investors jump on the bandwagon early before the Fda even approves it and proves that it works. But I think that if you look at the personality of the President, if he does get better in the next couple weeks, he's probably going to start talking about how these treatments are miracle treatments and that could lead investors to a flurry of hype like, uh, frankly, they're miracles. If you want to know the truth, they're miracles. People criticize me.

So yes, Regn is a very potential winner in this. But the problem with Regn at the same time is that it is trading pretty damn high. and I think that Gi Ld has the opposite problem. It is trading really low.

But but it's already true that their treatment already has a lot of legitimacy attached to it. So I have to go ahead and defer to you the viewer to decide which one you want to trade, but in reality have both on your watch list. Okay next. so with the President's condition being a focus this week, unless you are a fortune teller, you should not know whether or not this is going to be good news or bad news.

You can speculate all you want. So my take on this is that you should always be prepared by having the ability to play an uptrend and a downtrend. And because there's going to be a greater focus on Biopharma this week, instead of just betting on individual stocks, why don't you just trade all of Biopharma? and to that extent, Biotech? it's often helpful to trade the biotech sector itself. Labview allows us to exploit violently the upward movements in Biotech by leveraging movements upward, and Lab D allows us to exploit downward movements in the market.

And as we get developments this week, it's going to be important to have both of these in our arsenal. and I don't need to remind you how extremely useful these were. Last week, we had intense runs upward in Lab U and in Lab D as the news developed. so know these folks.

Okay, and lastly, I'm going to go ahead and point you to a bonus stock Carmax. Now, Carmax is an analyst darling, and throughout this entire year, every single dip has been a buying opportunity. It's also just been cut back on pretty decent earnings, although slightly poor guidance, but pretty decent earnings overall. Now, one of the things that I like about Carmax is it's sort of in this area where the analysts are going crazy, and while we do call the analyst monkeys, sometimes they do pick up on some accurate trends.

And one of the things that we've seen during this pandemic is an increase of carbine services such as Carvana such as rooms such as Carmax that specialize in both the buy side and the sell side and have a large internet focus. These types of companies are doing really, really, really well. People are taking the dealership out and all the inconvenience with dealerships out of the process. But enough with the fundamentals.

in terms of just the chart, this is a very, very strong play. We have all this momentum and we have a dip from its uptrend and now some signs of recovery. So the question is, will Carmax continue to run, Because if it does, there's a decent amount of upside to continue on the strengthening trend. Okay folks, well, there you have it.

If you have any questions, feel free to reach out to us in the comment section below or join us on Zip Trader Circle. In Zip Trader Circle, we post our nightly free watch lists, And by the way, if you don't have the ability to appropriately trade in the pre-market or the after hours, your broker doesn't allow you to trade those periods. Well, you're going to miss out on a lot of these moves, and you could fix that problem quite simply by signing up with a broker that allows you to trade in the pre-market or the after hours, such as Weeble. And Weeble is also offering two free stocks if you sign up and deposit with our link in the description below and one of those stocks can be valued up to this amount, so definitely worth trying out if you are broker curious.

Anyways, folks, good luck on the battlefields this week and well I'll see you in the next video.